Orchestra BioMed Holdings, Inc. Cash Flow Statement

Cash Flow Statement Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -32.66M-47.66M-60.95M
Depreciation and Depletion 0.22M0.29M
Share-based Compensation 3.38M7.62M10.62M
Gains from Sales and Divestitures 0.08M0.42M
Gains from Investment Securities 1.35M0.29M1.20M
Non-cash Items 8.19M3.49M
Cash from Operations -29.29M-46.13M-50.56M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.60M3.82M1.50M
Amortization of Deferred Charges 0.16M0.11M0.03M
Depreciation & Amortization (CF) 0.22M0.29M0.31M
Change in Working Capital
Change in Receivables -0.03M0.00M-0.02M
Change in Inventory 0.21M-0.13M0.03M
Change in Account Payables 0.38M
Change in Accured Expenses 3.35M0.14M2.97M
Investing Activities
Capital Expenditures 0.59M0.08M0.29M
Change in Acquisitions & Divestments 152.80M86.63M
Cash from Investing Activities -64.12M10.69M13.09M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Issuances 10.00M15.00M
Long-Term Debt Repayments 6.45M10.85M
Change in Capital Stock
Shares Issued 0.12M0.23M15.04M
Preferred Shares Issued 109.83M
Misc.
Cash from Financing Activities 103.26M46.22M29.17M
Change in Cash 9.85M10.78M-8.30M
Free Cash Flow -29.88M-46.20M-50.85M
Net Cash Flow 9.85M10.78M-8.30M